Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available.
Scope of the Report:
Asparaginase was approved for medical use in the United States in 1978. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.
The classification of Medical Asparaginase includes Escherichia coli, Erwinia Chrysanthemi and Pegylated, and the sales proportion of Escherichia coli in 2017 is about 64.6%, and the proportion is decreasing trend from 2013 to 2018.
Medical Asparaginase is widely sales for Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Others. The most proportion of Medical Asparaginase is sales in Acute Lymphoblastic Leukemia, and the consumption proportion is about 90% in 2017.
North America is the largest consumption place, with a revenue market share nearly 53.5% in 2017. Following North America, Europe is the second largest consumption place with the revenue market share of 37.2%, China is also an important sales region for the Medical Asparaginase, In China, the price is lower than the developed countries.
Market competition is intense. Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, etc. are the leaders of the industry. They hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
The worldwide market for Medical Asparaginase is expected to grow at a CAGR of roughly 1.5% over the next five years, will reach 430 million US$ in 2024, from 390 million US$ in 2019, according to a new study.
This report focuses on the Medical Asparaginase in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Jazz Pharmaceuticals
Shire
Medac GmbH
Kyowa Hakko Kirin
Qianhong Bio-pharma
Taj Pharmaceuticals
Mingxing Pharma
SL Pharma
United Biotech
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Escherichia coli
Erwinia Chrysanthemi
Pegylated
Market Segment by Applications, can be divided into
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Medical Asparaginase product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Medical Asparaginase, with price, sales, revenue and global market share of Medical Asparaginase in 2017 and 2018.
Chapter 3, the Medical Asparaginase competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Medical Asparaginase breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Medical Asparaginase market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Medical Asparaginase sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Scope of the Report:
Asparaginase was approved for medical use in the United States in 1978. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.
The classification of Medical Asparaginase includes Escherichia coli, Erwinia Chrysanthemi and Pegylated, and the sales proportion of Escherichia coli in 2017 is about 64.6%, and the proportion is decreasing trend from 2013 to 2018.
Medical Asparaginase is widely sales for Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Others. The most proportion of Medical Asparaginase is sales in Acute Lymphoblastic Leukemia, and the consumption proportion is about 90% in 2017.
North America is the largest consumption place, with a revenue market share nearly 53.5% in 2017. Following North America, Europe is the second largest consumption place with the revenue market share of 37.2%, China is also an important sales region for the Medical Asparaginase, In China, the price is lower than the developed countries.
Market competition is intense. Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, etc. are the leaders of the industry. They hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
The worldwide market for Medical Asparaginase is expected to grow at a CAGR of roughly 1.5% over the next five years, will reach 430 million US$ in 2024, from 390 million US$ in 2019, according to a new study.
This report focuses on the Medical Asparaginase in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Jazz Pharmaceuticals
Shire
Medac GmbH
Kyowa Hakko Kirin
Qianhong Bio-pharma
Taj Pharmaceuticals
Mingxing Pharma
SL Pharma
United Biotech
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Escherichia coli
Erwinia Chrysanthemi
Pegylated
Market Segment by Applications, can be divided into
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Medical Asparaginase product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Medical Asparaginase, with price, sales, revenue and global market share of Medical Asparaginase in 2017 and 2018.
Chapter 3, the Medical Asparaginase competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Medical Asparaginase breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Medical Asparaginase market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Medical Asparaginase sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
